Episode #10
The Genetics of GLP-1s: Why Two People on the Same Dose Get Different Results
In this episode of Beyond the Scale, Dr. Piper Gibson and I close the AIMPrint series with the subject we deliberately saved for last: what your genetics have to say about weight loss medications. We run a large weight loss practice in Pittsburgh, and we watch the same thing every week. Two patients, same medication, same dose, wildly different outcomes. Blood work alone did not explain it. This episode is about the part that does. We start at the receptor. GLP1R encodes the receptor that semaglutide binds to, so when that receptor is less functional, the medication simply has less to work with. Tirzepatide complicates it usefully, because it hits a second receptor, GIPR, tied to a separate gut hormone. Someone with strong GLP1R sensitivity and poor GIPR signaling may respond differently to one drug than the other. Dr. Gibson notes most prescribers choose based on availability and insurance, but genetics may deserve a seat at that table. GLP-1 medications enhance satiety signals, but those signals still need functional receptors to land, so a patient with a red leptin receptor and a red HTR2C may feel less full than expected even at a therapeutic dose. That's the person still hungry on the shot, and the fix is layering protein, fiber, and structured meal timing rather than chase the dose. We explore COMT and the dopamine side, where intermediate clearance may make someone a stronger responder, and where DRD2 and ANKK1 help explain people losing interest in alcohol and other compulsive behaviors, something Dr. Gibson experienced herself. We cover insulin resistance through TCF7L2 and CDKN2A layered with the mitochondrial picture, UCP and TFAM. Then we get to the part I don't hear enough practitioners discussing. GLP-1 medications do not selectively burn fat. A meaningful share of the loss is lean mass, and TRHR and IGF2 variants influence who is predisposed to catabolizing muscle in a deficit. That's why protein targets and resistance training belong in the conversation before the medication starts, and why some people look worse at their goal weight than they did heavier. We also cover who is set up for the nausea and GI misery that makes people quit inside 30 days, why FUT2 secretor status shapes your body's own GLP-1 production through the microbiome, the nutrient depletions that hit hardest long-term, including B12 and the vitamin D pathway, and what separates a 40 pound responder from an 8 pound one. Dr. Gibson's line is the one I keep repeating: prescribing without understanding these variants is like tuning an engine without knowing the car model. - - - - - About the Guest: Dr. Piper Gibson, PhD , is a functional-genetics practitioner who spends most of her clinical life with children and families navigating tics, Tourette's, ADHD, anxiety, and OCD. She helped shape the thinking behind our AIMPrint panel, and she was genuinely fired up about this one, because the pharmacogenetics of weight loss medication sits outside what she normally gets to talk about in her own practice. Her talent is translation. She takes a report full of gene names that read like code words and turns them into a plan a real person can follow. She's also refreshingly willing to use herself as the example, including what a GLP-1 did and didn't do for her personally, which makes this episode a lot more useful than the average expert interview. - - - - - Social Handles: Website: https://regenerating.health Instagram: https://instagram.com/regeneratinghealth - - - - - Connect with the show and Body by AIM360: Website: https://bodybyaim360.com Podcast: https://bodybyaim360.com/podcast Instagram: https://www.instagram.com/bodybyaim360 Facebook: https://www.facebook.com/bodybyaim360 Book a call: https://calendly.com/bodybyaim360/drtalks - - - - - PODCAST Thank you for listening. Please subscribe and share. This podcast is produced by DrTalks.com https://drtalks.com/channel-growth/
